Safi Biotherapeutics Receives $4.7 Million U.S. Defense Award Extension To Advance Manufactured Red Blood Cells
· pulse2.com · popularity 18/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Safi Biotherapeutics, a biotechnology company developing manufactured human red blood cells for civilian and military transfusions, has received a $4.7 million non-dilutive award extension from the U.S. government's Defense Health Program. The funding was provided through the Medical Technology Enterprise Consortium under the Combat Casualty Care portfolio and will support development activities required before Safi's first planned clinical trial. The post Safi Biotherapeutics Receives $4.7 Million U.S. Defense Award Extension To Advance Manufactured Red Blood Cells appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 12.